Ortho Clinical Diagnostics Holdings Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Ortho Clinical Diagnostics Holdings Plc (OCDX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Ortho Clinical Diagnostics Holdings Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 2,036M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-1.8% annualized vs trailing 12 months).
- Peer revenue share: Ortho Clinical Diagnostics Holdings Plc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OCDX Sales vs. its Competitors, Q1 2022
Ortho Clinical Diagnostics Holdings Plc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the In Vitro & In Vivo Diagnostic Substances industry grew revenue 2.5% year over year, combined, vs -1.3% for Ortho Clinical Diagnostics Holdings Plc. Ortho Clinical Diagnostics Holdings Plc's share of combined industry revenue moved from 15.17% to 14.61%, a loss of 0.56 percentage points.
Ortho Clinical Diagnostics Holdings Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Ortho Clinical Diagnostics Holdings Plc | No | Yes | Yes | No |
| High-Confidence Competitors (1) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 28.60 % (2 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OCDX Stock Performance relative to its Competitors
OCDX Stock Performance relative to High-Confidence Competitors
OCDX Stock Performance relative to Similar Growth & Profitability Competitors
Ortho Clinical Diagnostics Holdings Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Quanterix Corporation | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Ortho Clinical Diagnostics Holdings Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Ortho Clinical Diagnostics Holdings Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Ortho Clinical Diagnostics Holdings Plc | Reportable 87.72 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).